<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083186</url>
  </required_header>
  <id_info>
    <org_study_id>P11-978</org_study_id>
    <nct_id>NCT01083186</nct_id>
  </id_info>
  <brief_title>Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain data on the use of Zemplar (paricalcitol) capsules in
      real-life clinical practice in predialysis patients with chronic kidney disease (CKD) and
      secondary hyperparathyroidism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a single arm, open, multicenter, non-interventional, post marketing observational
      study, which has been conducted in 24 sites in Greece, under normal clinical practice and as
      per the locally approved Summary of Product Characteristics (SmPC) of study medication (oral
      paricalcitol). Eligible patients were followed up for a 12-month period after enrollment. All
      study activities were consistent with European Union (EU) directive 2001/20/EC section for
      non-interventional studies.

      In this study, paricalcitol was prescribed on an on-label basis in an everyday setting to
      observe drug actions in a distinct geography (Greece with &gt; 250 days/year of sunny days) as
      well as in a significant subpopulation (Chronic Kidney Disease [CKD] stages 3-5 transplanted
      patients). Dose tolerability, treatment effects, as well as maintenance of results were
      registered for a 12-month period in order to obtain experience in the long term use of
      paricalcitol capsules. Furthermore, in centers where additional blood parameters were
      examined as part of clinical routine, these were recorded and analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intact Parathormone (iPTH) Changes During the Study Time-Points for Overall Study Population</measure>
    <time_frame>Baseline, Enrollment Visit, Month 3, Month 6, Month 9, Month 12</time_frame>
    <description>iPTH levels before and after oral paricalcitol treatment onset were recorded at each study visit, and corresponding changes were calculated for the overall study population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intact Parathormone (iPTH) Changes During the Study Time-Points for Subpopulation of Renal Transplanted Participants</measure>
    <time_frame>Baseline, Enrollment Visit, Month 3, Month 6, Month 9, Month 12</time_frame>
    <description>iPTH levels before and after oral paricalcitol treatment onset were recorded at each study visit, and corresponding changes were calculated for the subpopulation of renal transplanted participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Attain the First Lower Intact Parathormone (iPTH) Levels</measure>
    <time_frame>Measured from start of study, up to a maximum of 12 months</time_frame>
    <description>The time to attain the first lower iPTH levels was considered as the time from the date of oral paricalcitol treatment onset until the date when any of the following conditions were initially met: a 30% reduction from iPTH levels prior to treatment onset had been achieved, for patients who were still outside the target range; or iPTH levels equal or lower to the upper limit of the target range according to Kidney Disease Quality Outcome Initiative (K/DOQI) guidelines (CKD Stage 3: ≤ 70 pg/mL; CKD Stage 4: ≤ 110 pg/mL; CKD Stage 5: ≤ 300 pg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Duration of Effect Sustainability (Months)</measure>
    <time_frame>Measured from start of study, up to a maximum of 12 months</time_frame>
    <description>The effect was considered sustainable if: the participant's intact parathormone (iPTH) value remained equal or lower to the upper limit of the target range according to Kidney Disease Quality Outcome Initiative (K/DOQI) guidelines (CKD Stage 3: ≤ 70 pg/mL; CKD Stage 4: ≤ 110 pg/mL); or iPTH levels continued to decrease 30% from the previous available measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Participants by Achievement of Intact Parathormone (iPTH) Levels Within the Target Range</measure>
    <time_frame>Enrollment Visit, Month 3, Month 6, Month 9, Month 12</time_frame>
    <description>Number of participants with iPTH levels within the target range of Kidney Disease Quality Outcome Initiative (K/DOQI) treatment guidelines at each study measurement after oral paricalcitol treatment onset. K/DOQI treatment guidelines: CKD Stage 3: 35-70 pg/mL; CKD Stage 4: 70-110 pg/mL during a 12-month period of treatment with oral paricalcitol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serum Calcium Level Abnormalities</measure>
    <time_frame>Baseline, Enrollment Visit, Month 6, Month 12</time_frame>
    <description>Normal serum calcium range was 8.4-10.2 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serum Phosphorus Level Abnormalities</measure>
    <time_frame>Baseline, Enrollment Visit, Month 6, Month 12</time_frame>
    <description>Normal serum phosphorus range was 2.7-4.6 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dipstick Albuminuria Grade From Baseline to Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The values &quot;-, Trace, +, ++, and +++&quot; are taken directly from the dipstick measurements, and represent a range from none to highest albuminuria. Data presented shows the number of participants with each value both at Baseline and at Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dipstick Albuminuria Grade From Baseline to Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>The values &quot;-, Trace, +, ++, and +++&quot; are taken directly from the dipstick measurements, and represent a range from none to highest albuminuria. Data presented shows the number of participants with each value both at Baseline and at Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Hemoglobin A1c (HbA1c) Values Throughout the Study</measure>
    <time_frame>Baseline, Enrollment Visit, Month 6, Month 12</time_frame>
    <description>The HbA1c normal range was 4.3-6.1%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-serious Adverse Events (nSAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From time of enrollment throughout the study up to 12 months for nSAEs. SAEs from time of enrollment throughout the study up to + 30 days after end of study.</time_frame>
    <description>In order to establish the safety profile of oral paricalcitol in daily clinical practice, non-serious adverse events (nSAEs) and serious adverse events (SAEs) were collected during the course of the study. An adverse event (AE) is defined as any untoward medical occurrence in a patient, which does not necessarily have a causal relationship with their treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, is a congenital anomaly or persistent or significant disability/incapacity or is an important medical event requiring medical or surgical intervention to prevent any of the outcomes listed above. Please see Adverse Events section below for more details.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Participants by Chronic Kidney Disease (CKD) Stage Throughout Study</measure>
    <time_frame>Baseline, Enrollment Visit, Month 3, Month 6, Month 9, Month 12</time_frame>
    <description>Change in CKD stage throughout the study period was assessed by the estimated glomerular filtration rate (eGFR) levels recorded by the physicians at each study time point. Classification of eGFR into CKD stages as follows: CKD stage 2: 60-89 mL/min/1.73m^2; CKD stage 3: 30-59 mL/min/1.73m^2; CKD stage 4: 15-29 mL/min/1.73m^2; CKD stage 5: &lt;15 mL/min/1.73/m^2. Table presents the number of participants by stage at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Glomerular Filtration Rate (eGFR) Values Throughout the Study</measure>
    <time_frame>Baseline, Enrollment Visit, Month 3, Month 6, Month 9, Month 12</time_frame>
    <description>The eGFR normal range was 90-120 mL/min/1.73m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alanine Aminotransferase (ALT) Levels at Months 6 and 12</measure>
    <time_frame>Baseline, Month 6, Month 12</time_frame>
    <description>The alanine aminotransferase normal range was 11-43 IU/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aspartate Aminotransferase (AST) Levels at Months 6 and 12</measure>
    <time_frame>Baseline, Month 6, Month 12</time_frame>
    <description>The aspartate aminotransferase normal range was 11-38 IU/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine Levels at Months 6 and 12</measure>
    <time_frame>Baseline, Month 6, Month 12</time_frame>
    <description>The creatinine normal range was 0.6-1.4 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urea Levels at Months 6 and 12</measure>
    <time_frame>Baseline, Month 6, Month 12</time_frame>
    <description>The urea normal range was 10-50 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase (ALP) Levels at Months 6 and 12</measure>
    <time_frame>Baseline, Month 6, Month 12</time_frame>
    <description>The alkaline phosphatase normal range was 40-129 IU/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Enrollment in Total Cholesterol Levels at Months 6 and 12</measure>
    <time_frame>Enrollment, Month 6, Month 12</time_frame>
    <description>The total cholesterol normal range was 130-200 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Enrollment in Triglyceride Levels at Months 6 and 12</measure>
    <time_frame>Enrollment, Month 6, Month 12</time_frame>
    <description>The normal range for triglycerides was 0-200 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Enrollment in Low Density Lipoprotein Cholesterol (LDL-C) Levels at Months 6 and 12</measure>
    <time_frame>Enrollment, Month 6, Month 12</time_frame>
    <description>The LDL-C normal range was 0-150 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Enrollment in High Density Lipoprotein Cholesterol (HDL-C) Levels at Months 6 and 12</measure>
    <time_frame>Enrollment, Month 6, Month 12</time_frame>
    <description>The HDL-C normal range was 35-90 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-Reactive Protein (CRP) Levels at Months 6 and 12</measure>
    <time_frame>Baseline, Month 6, Month 12</time_frame>
    <description>The CRP normal range was 0-0.6 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homocysteine Values Throughout the Study</measure>
    <time_frame>Baseline, Enrollment Visit, Month 6, Month 12</time_frame>
    <description>The homocysteine normal range 3.5-20 μmol/L.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Chronic Kidney Failure</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</arm_group_label>
    <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from 24 hospital-based specialty, nephrology clinics in Greece
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with secondary hyperparathyroidism in the presence of chronic kidney disease
             stage 3, 4 or 5 treated with Zemplar (paricalcitol) oral for at least 1 month prior to
             study enrollment

          -  Male and female (not pregnant or not planning to be pregnant in the next 12 months)
             patients &gt; 18 years of age

          -  Signed informed consent by subject

          -  Hypertensive and diabetic subjects must be on an optimal and steady medication regimen
             for more than 30 days

        Exclusion Criteria:

          -  Contraindications listed in the Summary of Product Characteristics for Zemplar
             capsules apply (Appendix I and II)

          -  Parathormone value of &gt; 1000 pg/mL (sign of tertiary hyperparathyroidism)

          -  Treatment with Vitamin D within the last 1 month prior to inclusion into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos Argyropoulos, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Pharmaceuticals S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47002</name>
      <address>
        <city>Arta</city>
        <zip>47100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43772</name>
      <address>
        <city>Athens</city>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27492</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43769</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38257</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47003</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27497</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47004</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27489</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27495</name>
      <address>
        <city>Athens</city>
        <zip>16673</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43773</name>
      <address>
        <city>Athens</city>
        <zip>17237</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27498</name>
      <address>
        <city>Haidari, Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38259</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 22121</name>
      <address>
        <city>Larissa</city>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43771</name>
      <address>
        <city>Larissa</city>
        <zip>41223</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43767</name>
      <address>
        <city>Maroussi Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27496</name>
      <address>
        <city>Nikaia</city>
        <zip>18454</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43768</name>
      <address>
        <city>North Ionia, Athens</city>
        <zip>142 33</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27491</name>
      <address>
        <city>Piraeus</city>
        <zip>18536</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27494</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27493</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38255</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43770</name>
      <address>
        <city>Thessaloniki</city>
        <zip>570 01</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39839</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related info</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <results_first_submitted>January 31, 2013</results_first_submitted>
  <results_first_submitted_qc>January 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2013</results_first_posted>
  <last_update_submitted>March 11, 2013</last_update_submitted>
  <last_update_submitted_qc>March 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary Hyperparathyroidism</keyword>
  <keyword>Chronic Kidney Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
          <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="406"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hemodialysis Initiation</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance to Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
          <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intact Parathormone (iPTH) Changes During the Study Time-Points for Overall Study Population</title>
        <description>iPTH levels before and after oral paricalcitol treatment onset were recorded at each study visit, and corresponding changes were calculated for the overall study population.</description>
        <time_frame>Baseline, Enrollment Visit, Month 3, Month 6, Month 9, Month 12</time_frame>
        <population>Overall study population. n=number of participants with available data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Intact Parathormone (iPTH) Changes During the Study Time-Points for Overall Study Population</title>
          <description>iPTH levels before and after oral paricalcitol treatment onset were recorded at each study visit, and corresponding changes were calculated for the overall study population.</description>
          <population>Overall study population. n=number of participants with available data at given time-point.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=495</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232.1" spread="168.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1 (Enrollment); n=497</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.1" spread="141.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (3 Months Post-Enrollment); n=432</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.6" spread="137.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (6 Months Post-Enrollment); n=405</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.3" spread="172.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (9 Months Post-Enrollment); n=378</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.2" spread="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (12 Months Post-Enrollment); n=368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.4" spread="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Enrollment; n=492</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.2" spread="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 2; n=429</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.6" spread="125.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3; n=402</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.7" spread="172.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 4; n=376</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.4" spread="129.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5; n=364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-96.1" spread="130.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Enrollment to Visit 2; n=430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.6" spread="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Enrollment to Visit 3; n=404</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.9" spread="150.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Enrollment to Visit 4; n=378</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.4" spread="112.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Enrollment to Visit 5; n=367</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.4" spread="113.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intact Parathormone (iPTH) Changes During the Study Time-Points for Subpopulation of Renal Transplanted Participants</title>
        <description>iPTH levels before and after oral paricalcitol treatment onset were recorded at each study visit, and corresponding changes were calculated for the subpopulation of renal transplanted participants.</description>
        <time_frame>Baseline, Enrollment Visit, Month 3, Month 6, Month 9, Month 12</time_frame>
        <population>Participants with renal transplantation history. n=number of participants with available data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Intact Parathormone (iPTH) Changes During the Study Time-Points for Subpopulation of Renal Transplanted Participants</title>
          <description>iPTH levels before and after oral paricalcitol treatment onset were recorded at each study visit, and corresponding changes were calculated for the subpopulation of renal transplanted participants.</description>
          <population>Participants with renal transplantation history. n=number of participants with available data at given time-point.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321.5" spread="293.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1 (Enrollment); n=39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.3" spread="214.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (3 Months Post-Enrollment); n=27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.1" spread="166.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (6 Months Post-Enrollment); n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.4" spread="225.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (9 Months Post-Enrollment); n=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.7" spread="231.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (12 Months Post-Enrollment); n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.9" spread="109.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Enrollment; n=39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.1" spread="144.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 2; n=27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-93.0" spread="134.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3; n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-95.4" spread="262.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 4; n=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71.3" spread="228.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5; n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92.5" spread="139.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Enrollment to Visit 2; n=26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.3" spread="106.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Enrollment to Visit 3; n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.1" spread="215.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Enrollment to Visit 4; n=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.0" spread="207.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Enrollment to Visit 5; n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.1" spread="144.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Attain the First Lower Intact Parathormone (iPTH) Levels</title>
        <description>The time to attain the first lower iPTH levels was considered as the time from the date of oral paricalcitol treatment onset until the date when any of the following conditions were initially met: a 30% reduction from iPTH levels prior to treatment onset had been achieved, for patients who were still outside the target range; or iPTH levels equal or lower to the upper limit of the target range according to Kidney Disease Quality Outcome Initiative (K/DOQI) guidelines (CKD Stage 3: ≤ 70 pg/mL; CKD Stage 4: ≤ 110 pg/mL; CKD Stage 5: ≤ 300 pg/mL).</description>
        <time_frame>Measured from start of study, up to a maximum of 12 months</time_frame>
        <population>Subset of participants with baseline CKD stage ≥ 3 as well as with available iPTH values greater than the upper limit of the target range, prior to paricalcitol treatment onset. Target range for this specific analysis was defined based on patient’s CKD stage (per baseline eGFR) prior to paricalcitol treatment onset.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Attain the First Lower Intact Parathormone (iPTH) Levels</title>
          <description>The time to attain the first lower iPTH levels was considered as the time from the date of oral paricalcitol treatment onset until the date when any of the following conditions were initially met: a 30% reduction from iPTH levels prior to treatment onset had been achieved, for patients who were still outside the target range; or iPTH levels equal or lower to the upper limit of the target range according to Kidney Disease Quality Outcome Initiative (K/DOQI) guidelines (CKD Stage 3: ≤ 70 pg/mL; CKD Stage 4: ≤ 110 pg/mL; CKD Stage 5: ≤ 300 pg/mL).</description>
          <population>Subset of participants with baseline CKD stage ≥ 3 as well as with available iPTH values greater than the upper limit of the target range, prior to paricalcitol treatment onset. Target range for this specific analysis was defined based on patient’s CKD stage (per baseline eGFR) prior to paricalcitol treatment onset.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="7.2" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Duration of Effect Sustainability (Months)</title>
        <description>The effect was considered sustainable if: the participant’s intact parathormone (iPTH) value remained equal or lower to the upper limit of the target range according to Kidney Disease Quality Outcome Initiative (K/DOQI) guidelines (CKD Stage 3: ≤ 70 pg/mL; CKD Stage 4: ≤ 110 pg/mL); or iPTH levels continued to decrease 30% from the previous available measurement.</description>
        <time_frame>Measured from start of study, up to a maximum of 12 months</time_frame>
        <population>All evaluable participants</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Duration of Effect Sustainability (Months)</title>
          <description>The effect was considered sustainable if: the participant’s intact parathormone (iPTH) value remained equal or lower to the upper limit of the target range according to Kidney Disease Quality Outcome Initiative (K/DOQI) guidelines (CKD Stage 3: ≤ 70 pg/mL; CKD Stage 4: ≤ 110 pg/mL); or iPTH levels continued to decrease 30% from the previous available measurement.</description>
          <population>All evaluable participants</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Participants by Achievement of Intact Parathormone (iPTH) Levels Within the Target Range</title>
        <description>Number of participants with iPTH levels within the target range of Kidney Disease Quality Outcome Initiative (K/DOQI) treatment guidelines at each study measurement after oral paricalcitol treatment onset. K/DOQI treatment guidelines: CKD Stage 3: 35–70 pg/mL; CKD Stage 4: 70–110 pg/mL during a 12-month period of treatment with oral paricalcitol.</description>
        <time_frame>Enrollment Visit, Month 3, Month 6, Month 9, Month 12</time_frame>
        <population>All participants. n=participants with evaluable data at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants Within the iPTH Target Range</title>
            <description>Number of participants with iPTH levels within the target range of K/DOQI treatment guidelines: CKD Stage 3: 35-70 pg/mL; CKD Stage 4: 70-110 pg/mL during a 12-month period of treatment with oral paricalcitol.</description>
          </group>
          <group group_id="O2">
            <title>Participants Out of the iPTH Target Range</title>
            <description>Number of participants with iPTH levels outside of the target range of K/DOQI treatment guidelines: CKD Stage 3: 35-70 pg/mL; CKD Stage 4: 70-110 pg/mL during a 12-month period of treatment with oral paricalcitol.</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Participants by Achievement of Intact Parathormone (iPTH) Levels Within the Target Range</title>
          <description>Number of participants with iPTH levels within the target range of Kidney Disease Quality Outcome Initiative (K/DOQI) treatment guidelines at each study measurement after oral paricalcitol treatment onset. K/DOQI treatment guidelines: CKD Stage 3: 35–70 pg/mL; CKD Stage 4: 70–110 pg/mL during a 12-month period of treatment with oral paricalcitol.</description>
          <population>All participants. n=participants with evaluable data at given time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Enrollment); n=497</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (3 Months Post-Enrollment); n=432</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (6 Months Post-Enrollment); n=405</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (9 Months Post-Enrollment); n=378</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (12 Months Post-Enrollment); n=368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serum Calcium Level Abnormalities</title>
        <description>Normal serum calcium range was 8.4-10.2 mg/dL.</description>
        <time_frame>Baseline, Enrollment Visit, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants Within the Normal Calcium Range</title>
            <description>Normal serum calcium range was 8.4-10.2 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Participants Outside of the Normal Calcium Range</title>
            <description>Normal serum calcium range was 8.4-10.2 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serum Calcium Level Abnormalities</title>
          <description>Normal serum calcium range was 8.4-10.2 mg/dL.</description>
          <population>All participants. n=number of participants with evaluable data at given time-point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=461</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1 (Enrollment); n=471</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (6 Months Post-Enrollment); n=436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (12 Months Post-Enrollment); n=386</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serum Phosphorus Level Abnormalities</title>
        <description>Normal serum phosphorus range was 2.7-4.6 mg/dL.</description>
        <time_frame>Baseline, Enrollment Visit, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-point</population>
        <group_list>
          <group group_id="O1">
            <title>Participants Within the Phosphorus Normal Range</title>
            <description>Normal serum phosphorus range was 2.7-4.6 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Participants Outside of the Phosphorus Normal Range</title>
            <description>Normal serum phosphorus range was 2.7-4.6 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serum Phosphorus Level Abnormalities</title>
          <description>Normal serum phosphorus range was 2.7-4.6 mg/dL.</description>
          <population>All participants. n=number of participants with evaluable data at given time-point</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=451</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1 (Enrollment); n=466</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (6 Months Post-Enrollment); n=429</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (12 Months Post-Enrollment); n=375</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dipstick Albuminuria Grade From Baseline to Month 6</title>
        <description>The values “-, Trace, +, ++, and +++” are taken directly from the dipstick measurements, and represent a range from none to highest albuminuria. Data presented shows the number of participants with each value both at Baseline and at Month 6.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Number of participants with evaluable data at both Baseline and Visit 3 (6 Months Post-Enrollment)</population>
        <group_list>
          <group group_id="O1">
            <title>No Albuminuria at Month 6</title>
            <description>The value &quot;-&quot; is taken directly from the dipstick measurements, and represents a reading of no albuminuria.</description>
          </group>
          <group group_id="O2">
            <title>Trace Albuminuria at Month 6</title>
            <description>The value &quot;Trace&quot; is taken directly from the dipstick measurements, and represents a reading of trace albuminuria.</description>
          </group>
          <group group_id="O3">
            <title>&quot;+&quot; Albuminuria at Month 6</title>
            <description>The value &quot;+&quot; is taken directly from the dipstick measurements, and represents the middle of a range from none to highest albuminuria.</description>
          </group>
          <group group_id="O4">
            <title>&quot;++&quot; Albuminuria at Month 6</title>
            <description>The value &quot;++&quot; is taken directly from the dipstick measurements, and represents the value second to highest albuminuria.</description>
          </group>
          <group group_id="O5">
            <title>&quot;+++&quot; Albuminuria at Month 6</title>
            <description>The value &quot;+++&quot; is taken directly from the dipstick measurements, and represents the highest albuminuria.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dipstick Albuminuria Grade From Baseline to Month 6</title>
          <description>The values “-, Trace, +, ++, and +++” are taken directly from the dipstick measurements, and represent a range from none to highest albuminuria. Data presented shows the number of participants with each value both at Baseline and at Month 6.</description>
          <population>Number of participants with evaluable data at both Baseline and Visit 3 (6 Months Post-Enrollment)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="162"/>
                <count group_id="O4" value="162"/>
                <count group_id="O5" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade &quot;-&quot; at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade &quot;Trace&quot; at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade &quot;+&quot; at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade &quot;++&quot; at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade &quot;+++&quot; at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dipstick Albuminuria Grade From Baseline to Month 12</title>
        <description>The values “-, Trace, +, ++, and +++” are taken directly from the dipstick measurements, and represent a range from none to highest albuminuria. Data presented shows the number of participants with each value both at Baseline and at Month 6.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Number of participants with evaluable data at both Baseline and Visit 5 (12 Months Post-Enrollment)</population>
        <group_list>
          <group group_id="O1">
            <title>No Albuminuria at Month 12</title>
            <description>The value &quot;-&quot; is taken directly from the dipstick measurements, and represents a reading of no albuminuria.</description>
          </group>
          <group group_id="O2">
            <title>Trace Albuminuria at Month 12</title>
            <description>The value &quot;Trace&quot; is taken directly from the dipstick measurements, and represents a reading of trace albuminuria.</description>
          </group>
          <group group_id="O3">
            <title>&quot;+&quot; Albuminuria at Month 12</title>
            <description>The value &quot;+&quot; is taken directly from the dipstick measurements, and represents the middle of a range from none to highest albuminuria.</description>
          </group>
          <group group_id="O4">
            <title>&quot;++&quot; Albuminuria at Month 12</title>
            <description>The value &quot;++&quot; is taken directly from the dipstick measurements, and represents the value second to highest albuminuria.</description>
          </group>
          <group group_id="O5">
            <title>&quot;+++&quot; Albuminuria at Month 12</title>
            <description>The value &quot;+++&quot; is taken directly from the dipstick measurements, and represents the highest albuminuria.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dipstick Albuminuria Grade From Baseline to Month 12</title>
          <description>The values “-, Trace, +, ++, and +++” are taken directly from the dipstick measurements, and represent a range from none to highest albuminuria. Data presented shows the number of participants with each value both at Baseline and at Month 6.</description>
          <population>Number of participants with evaluable data at both Baseline and Visit 5 (12 Months Post-Enrollment)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="149"/>
                <count group_id="O5" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade &quot;-&quot; at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade &quot;Trace&quot; at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade &quot;+&quot; at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade &quot;++&quot; at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade &quot;+++&quot; at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycosylated Hemoglobin A1c (HbA1c) Values Throughout the Study</title>
        <description>The HbA1c normal range was 4.3-6.1%.</description>
        <time_frame>Baseline, Enrollment Visit, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Hemoglobin A1c (HbA1c) Values Throughout the Study</title>
          <description>The HbA1c normal range was 4.3-6.1%.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1 (Enrollment); n=99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (6 Months Post-Enrollment); n=76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (12 Months Post-Enrollment); n=69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-serious Adverse Events (nSAEs) and Serious Adverse Events (SAEs)</title>
        <description>In order to establish the safety profile of oral paricalcitol in daily clinical practice, non-serious adverse events (nSAEs) and serious adverse events (SAEs) were collected during the course of the study. An adverse event (AE) is defined as any untoward medical occurrence in a patient, which does not necessarily have a causal relationship with their treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, is a congenital anomaly or persistent or significant disability/incapacity or is an important medical event requiring medical or surgical intervention to prevent any of the outcomes listed above. Please see Adverse Events section below for more details.</description>
        <time_frame>From time of enrollment throughout the study up to 12 months for nSAEs. SAEs from time of enrollment throughout the study up to + 30 days after end of study.</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Non-serious Adverse Events (nSAEs) and Serious Adverse Events (SAEs)</title>
          <description>In order to establish the safety profile of oral paricalcitol in daily clinical practice, non-serious adverse events (nSAEs) and serious adverse events (SAEs) were collected during the course of the study. An adverse event (AE) is defined as any untoward medical occurrence in a patient, which does not necessarily have a causal relationship with their treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, is a congenital anomaly or persistent or significant disability/incapacity or is an important medical event requiring medical or surgical intervention to prevent any of the outcomes listed above. Please see Adverse Events section below for more details.</description>
          <population>All participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events (nSAEs and SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nSAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Participants by Chronic Kidney Disease (CKD) Stage Throughout Study</title>
        <description>Change in CKD stage throughout the study period was assessed by the estimated glomerular filtration rate (eGFR) levels recorded by the physicians at each study time point. Classification of eGFR into CKD stages as follows: CKD stage 2: 60-89 mL/min/1.73m^2; CKD stage 3: 30-59 mL/min/1.73m^2; CKD stage 4: 15-29 mL/min/1.73m^2; CKD stage 5: &lt;15 mL/min/1.73/m^2. Table presents the number of participants by stage at each study visit.</description>
        <time_frame>Baseline, Enrollment Visit, Month 3, Month 6, Month 9, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>CKD Stage 2</title>
            <description>Participants with chronic kidney disease stage 2 (eGFR 60-89 mL/min/1.73m^2) with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
          <group group_id="O2">
            <title>CKD Stage 3</title>
            <description>Participants with chronic kidney disease stage 3 (eGFR 30-59 mL/min/1.73m^2)with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
          <group group_id="O3">
            <title>CKD Stage 4</title>
            <description>Participants with chronic kidney disease stage 4 (eGFR 15-29 mL/min/1.73m^2)with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
          <group group_id="O4">
            <title>CKD Stage 5</title>
            <description>Participants with chronic kidney disease stage 5 (eGFR &lt;15 mL/min/1.73m^2)with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Participants by Chronic Kidney Disease (CKD) Stage Throughout Study</title>
          <description>Change in CKD stage throughout the study period was assessed by the estimated glomerular filtration rate (eGFR) levels recorded by the physicians at each study time point. Classification of eGFR into CKD stages as follows: CKD stage 2: 60-89 mL/min/1.73m^2; CKD stage 3: 30-59 mL/min/1.73m^2; CKD stage 4: 15-29 mL/min/1.73m^2; CKD stage 5: &lt;15 mL/min/1.73/m^2. Table presents the number of participants by stage at each study visit.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="500"/>
                <count group_id="O4" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Enrollment); n=500</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="234"/>
                    <measurement group_id="O3" value="266"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (3 Months Post-Enrollment); n=463</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="214"/>
                    <measurement group_id="O3" value="214"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (6 Months Post-Enrollment); n=451</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="197"/>
                    <measurement group_id="O3" value="210"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (9 Months Post-Enrollment); n=426</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="190"/>
                    <measurement group_id="O3" value="185"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (12 Months Post-Enrollment); n=406</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="184"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Glomerular Filtration Rate (eGFR) Values Throughout the Study</title>
        <description>The eGFR normal range was 90-120 mL/min/1.73m^2.</description>
        <time_frame>Baseline, Enrollment Visit, Month 3, Month 6, Month 9, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR) Values Throughout the Study</title>
          <description>The eGFR normal range was 90-120 mL/min/1.73m^2.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=499</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1 (Enrollment); n=500</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (3 Months Post-Enrollment); n=463</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (6 Months Post-Enrollment); n=451</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (9 Months Post-Enrollment); n=426</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (12 Months Post-Enrollment); n=406</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alanine Aminotransferase (ALT) Levels at Months 6 and 12</title>
        <description>The alanine aminotransferase normal range was 11-43 IU/L.</description>
        <time_frame>Baseline, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Aminotransferase (ALT) Levels at Months 6 and 12</title>
          <description>The alanine aminotransferase normal range was 11-43 IU/L.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=367</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3 (6 Months); n=276</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5 (12 months); n=259</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aspartate Aminotransferase (AST) Levels at Months 6 and 12</title>
        <description>The aspartate aminotransferase normal range was 11-38 IU/L.</description>
        <time_frame>Baseline, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Aminotransferase (AST) Levels at Months 6 and 12</title>
          <description>The aspartate aminotransferase normal range was 11-38 IU/L.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3 (6 Months); n=276</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5 (12 months); n=257</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine Levels at Months 6 and 12</title>
        <description>The creatinine normal range was 0.6-1.4 mg/dL.</description>
        <time_frame>Baseline, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine Levels at Months 6 and 12</title>
          <description>The creatinine normal range was 0.6-1.4 mg/dL.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=499</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3 (6 Months); n=450</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5 (12 months); n=406</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urea Levels at Months 6 and 12</title>
        <description>The urea normal range was 10-50 mg/dL.</description>
        <time_frame>Baseline, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urea Levels at Months 6 and 12</title>
          <description>The urea normal range was 10-50 mg/dL.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" spread="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3 (6 Months); n=443</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5 (12 months); n=399</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alkaline Phosphatase (ALP) Levels at Months 6 and 12</title>
        <description>The alkaline phosphatase normal range was 40-129 IU/L.</description>
        <time_frame>Baseline, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase (ALP) Levels at Months 6 and 12</title>
          <description>The alkaline phosphatase normal range was 40-129 IU/L.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=329</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.0" spread="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3 (6 Months); n=245</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5 (12 months); n=215</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Enrollment in Total Cholesterol Levels at Months 6 and 12</title>
        <description>The total cholesterol normal range was 130-200 mg/dL.</description>
        <time_frame>Enrollment, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Enrollment in Total Cholesterol Levels at Months 6 and 12</title>
          <description>The total cholesterol normal range was 130-200 mg/dL.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Enrollment); n=367</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.3" spread="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Enrollment to Visit 3 (6 Months);n=272</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Enrollment to Visit 5(12 months);n=243</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Enrollment in Triglyceride Levels at Months 6 and 12</title>
        <description>The normal range for triglycerides was 0-200 mg/dL.</description>
        <time_frame>Enrollment, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Enrollment in Triglyceride Levels at Months 6 and 12</title>
          <description>The normal range for triglycerides was 0-200 mg/dL.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Enrollment); n=353</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.0" spread="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3 (6 Months); n=259</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5 (12 months); n=228</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Enrollment in Low Density Lipoprotein Cholesterol (LDL-C) Levels at Months 6 and 12</title>
        <description>The LDL-C normal range was 0-150 mg/dL.</description>
        <time_frame>Enrollment, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Enrollment in Low Density Lipoprotein Cholesterol (LDL-C) Levels at Months 6 and 12</title>
          <description>The LDL-C normal range was 0-150 mg/dL.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Enrollment); n=234</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.8" spread="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3 (6 Months); n=144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5 (12 months); n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Enrollment in High Density Lipoprotein Cholesterol (HDL-C) Levels at Months 6 and 12</title>
        <description>The HDL-C normal range was 35-90 mg/dL.</description>
        <time_frame>Enrollment, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Enrollment in High Density Lipoprotein Cholesterol (HDL-C) Levels at Months 6 and 12</title>
          <description>The HDL-C normal range was 35-90 mg/dL.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Enrollment (Visit 1); n=271</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3 (6 Months); n=193</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5 (12 Months); n=166</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-Reactive Protein (CRP) Levels at Months 6 and 12</title>
        <description>The CRP normal range was 0-0.6 mg/dL.</description>
        <time_frame>Baseline, Month 6, Month 12</time_frame>
        <population>All participants. n=number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-Reactive Protein (CRP) Levels at Months 6 and 12</title>
          <description>The CRP normal range was 0-0.6 mg/dL.</description>
          <population>All participants. n=number of participants with evaluable data at given time-points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=149</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 3 (6 Months); n=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 5 (12 Months); n=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homocysteine Values Throughout the Study</title>
        <description>The homocysteine normal range 3.5-20 μmol/L.</description>
        <time_frame>Baseline, Enrollment Visit, Month 6, Month 12</time_frame>
        <population>All participants. n=the number of participants with evaluable data at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
            <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Homocysteine Values Throughout the Study</title>
          <description>The homocysteine normal range 3.5-20 μmol/L.</description>
          <population>All participants. n=the number of participants with evaluable data at given time-points.</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Study Treatment (Baseline); n=16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1 (Enrollment); n=52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (3 Months Post-Enrollment); n=35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (6 Months Post-Enrollment); n=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (9 Months Post-Enrollment); n=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (12 Months Post-Enrollment); n=13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were collected during the study up to 12 months. Serious adverse events were collected up to 30 days after the end of study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism</title>
          <description>Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fluid intake reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bone neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Kidney Failure</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

